|
|
Volumn 10, Issue 1, 2008, Pages 37-47
|
|
Cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin in the treatment of chronic hepatitis C in HIV-HCV co-infection;Costo efficacia di peginterferone α-2a + ribavirina versus peginterferone α-2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti HIV co-infetti
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;
PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ARTICLE;
COST EFFECTIVENESS ANALYSIS;
DISEASE COURSE;
DRUG COST;
FEMALE;
HEPATITIS C;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MAJOR CLINICAL STUDY;
MALE;
MIXED INFECTION;
PROBABILITY;
QUALITY OF LIFE;
RISK BENEFIT ANALYSIS;
SENSITIVITY ANALYSIS;
TREATMENT DURATION;
VIROLOGY;
|
|
EID: 40049108125
PISSN: 15909158
EISSN: None
Source Type: Journal
DOI: 10.1007/BF03320639 Document Type: Article |
|
Times cited : (4)
|
|
References (29)
|
